StockAnalyzer

Financial Analysis

DashboardSectorsComparablesScreenerUniverseMicrocapsAI 2nd OrderTheme MapEnergy & MaterialsMacroWatchlistCompareMi CarteraPortfolio

Recent

v0.1
AN1.AX$0.01+0.00%
Fair $0.01+0.0%

AN1.AX

Anagenics Limited

Consumer Defensive / Household & Personal ProductsASX

$0.01

+0.00 (+0.00%)

Fairly Valued+0.0%Fair Value $0.01Fund rank 30/100 · Data gapFallback financials|
SA 21/D
F-Score: 3/9
Low Profitability

FCF base 3Y

n/d

n/d CAGR · yield n/d

FCF base 5Y

n/d

n/d base · n/d expected

Precio de entrada

n/d

MOS 33% · confianza 24%

FCF escenarios

weak_data · normalized FCF $-1.8M · quality 72.3/100

Data gap 30/100
Bear 5Yn/dn/d
Base 5Yn/dn/d
Bull 5Yn/dn/d
Return 0/100Downside 20/100Model quality 41/100Data QA 20/100

Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.

Quality + valuation scorecard

SA Score

21/100

D

Piotroski

3/9

balance/quality

Valuation

50/100

+0.0% upside

5Y CAGR

+0.0%

50/100

Data QA

16/100

SEC 0%

Latest source: unknownPeriods: 4Warnings: 1unknown: 4
No SEC-backed annual rows; valuation uses fallback financial data. Insufficient audited annual history (<3 SEC-backed years); composite fair value and forward targets are disabled until manually verified. ROE is -67.7%, below the 5% threshold
Thesis & Journal · AN1.AXLocal privado en este navegador · Anagenics Limited
Plantilla tipo buy-side: tesis, bull/base/bear, catalizadores, riesgos, kill criteria y fecha de revisión. Esto no gasta GPT-5.5; luego lo usamos como contexto del memo.

Sin guardar todavía.

Market Cap

$7M

P/E

N/A

•

EV/EBITDA

N/A

•

ROE

-67.7%

↓

Gross Margin

42.9%

↑

Debt/Equity

0.46

↑
52-Week Range$0
$0$0

TradingView lightweight chart

AN1.AX price, volumen y niveles de valoración

Último $0.007Periodo -99.8%
Fair value: $0.007

Price & Ratios

Absolute Values (Left Axis)

Ratios / Percentages (Right Axis)

Financial statement dashboard

Crecimiento, márgenes y provenance

2022–2025 · 3 años de histórico normalizado

Revenue CAGR

-19.9%

FCF CAGR

—

FCF margin

-33.2%

FCF / Net income

1.28x

Latest source

Provider fallback

Margin decomposition

Último año: revenue $4.7M · net income $-1.2M · FCF $-1.6M

2022-FY → 2025-FY

Gross margin

42.9%-11.9% pts

Operating margin

-27.8%+21.6% pts

Net margin

-26.0%+13.5% pts

FCF margin

-33.2%-5.5% pts
MetricTTM
2025
2024
2023
2022
Income Statement
Revenue$4.7M$4.7M$10.8M$9.1M$9.2M
Net Income$-1.2M$-1.2M$-7.7M$-2.7M$-3.6M
EBITDA$-994774.00$-994774.00$-6.9M$-1.3M$-3.1M
EPS-0.00-0.00-0.02-0.01-0.02
Gross Margin42.9%42.9%40.4%48.4%54.8%
Operating Margin-27.8%-27.8%-68.3%-25.6%-49.4%
Net Margin-26.0%-26.0%-71.7%-29.3%-39.5%
Balance Sheet
Debt/Equity0.460.460.290.070.21
Current Ratio1.101.10———
Cash Flow
Free Cash Flow$-1.6M$-1.6M$-1.8M$-1.8M$-2.6M
Returns
ROE-67.7%-67.7%-285.8%-30.0%-44.0%
Valuation
P/B1.801.801.180.480.83
Growth & Yield
Revenue Growth-56.1%-56.1%18.5%-1.3%—
EPS Growth86.7%86.7%-95.0%42.0%—

Revenue, Net Income & Free Cash Flow ($B)

Margins (%)

Returns (%)

Leverage & Liquidity

Reverse DCF · market-implied EPS growthterminal P/E 15.0x · COE 10.0%
Reverse DCF requires positive EPS; loss-making or zero-EPS companies cannot produce a clean EPS hurdle.

Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.

Return attribution · 1Y approxreconcilia total +16.7%

Total return

+16.7%

Start / end P/E

n/dx → n/dx

EPS bridge

-0.02 → -0.00

Residual

+16.7%

EPS growthn/d
Multiple reratingn/d
Dividend+0.0%
Residual / FX / buybacks / cross-term+16.7%

EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.

Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.